recast-jats-buildd8e1462159jitcJ Immunother Cancer40425Journal for ImmunoTherapy of CancerJ Immunother Cancer2051-1426BMJ Publishing Group Ltds40425-019-0792-979210.1186/s40425-019-0792-931694703/jitc/7/1/285.atomCorrectionCorrection to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institutionFlorouVaia1aRosenbergAndrew E.1WiederEric1KomanduriKrishna V.1KoloniasDespina1UdumanMohamed2CastleJohn C.2BuellJennifer S.2TrentJonathan C.1WilkyBreelyn A.1 0000 0004 1936 8606grid.26790.3aDepartment of Medicine, Division of OncologySylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine 1475 NW 12th Avenue 33136 Miami FL USA 0000 0004 0486 2652grid.420152.0Agenus Inc. 3 Forbes Road 02421 Lexington MA USA vaia.florou@hsc.utah.edu 12201961120191811201918112019611201971285© The Author(s).2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells”.

publisher-imprint-nameBioMed Centralvolume-issue-count2issue-article-count0issue-toc-levels0issue-pricelist-year2019issue-copyright-holderThe Author(s)issue-copyright-year2019article-contains-esmNoarticle-numbering-styleUnnumberedarticle-registration-date-year2019article-registration-date-month10article-registration-date-day29article-toc-levels0toc-levels0volume-typeRegularjournal-productArchiveJournalnumbering-styleUnnumberedarticle-grants-typeOpenChoicemetadata-grantOpenAccessabstract-grantOpenAccessbodypdf-grantOpenAccessbodyhtml-grantOpenAccessbibliography-grantOpenAccessesm-grantOpenAccessonline-firstfalsepdf-file-referenceBodyRef/PDF/40425_2019_Article_792.pdfpdf-typeTypesettarget-typeOnlinePDFissue-typeRegulararticle-typeErratumjournal-subject-primaryMedicine & Public Healthjournal-subject-secondaryOncologyjournal-subject-secondaryImmunologyjournal-subject-collectionMedicineopen-accesstrue

The original article can be found online at 10.1186/s40425-019-0689-7

Correction to: J ImmunoTher Cancer

https://doi.org/10.1186/s40425-019-0689-7

Following publication of the original article [1], the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells.”

should be replaced with

“Ipilimumab and AGEN1884 are IgG1 class antibodies. AGEN1884 data show CTLA-4 inhibition and activity against T regulatory cells (reference 8).”

Reference Florou , et al . Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J ImmunoTher Cancer. 2019;7:213 doi:10.1186/s40425-019-0689-7 6686562